Development and Characterization of a Transgenic Mouse Model of Cytokine-Mediated Prostate Inflammation
Loading...
Links to Files
Permanent Link
Collections
Author/Creator
Author/Creator ORCID
Date
2016-01-01
Type of Work
Department
Biological Sciences
Program
Biological Sciences
Citation of Original Publication
Rights
This item may be protected under Title 17 of the U.S. Copyright Law. It is made available by UMBC for non-commercial research and education. For permission to publish or reproduce, please see http://aok.lib.umbc.edu/specoll/repro.php or contact Special Collections at speccoll(at)umbc.edu
Distribution Rights granted to UMBC by the author.
Distribution Rights granted to UMBC by the author.
Abstract
A causal link between prostate inflammation and prostate diseases including prostatitis, benign prostatic hyperplasia (BPH) and prostate cancer is unclear. This can be attributed to the fact that prostate inflammation is an extremely common histological finding. However, epidemiological, histopathological and molecular evidence suggest that inflammation may play a causal role in prostatitis, BPH and prostate adenocarcinoma. Discerning molecular mechanisms of chronic inflammation is almost impossible to do in humans. However, a physiologically relevant mouse model that encompasses prostate inflammation and its sequela could be highly informative. In this study, an innovative mouse model was developed that allows inducible expression of Interleukin 1B. Interleukin 1B is a proinflammatory cytokine implicated in major diseases including solid tumors, autoimmune disorders and neurodegenerative disorders. This potent cytokine is implicated in chronic prostatitis and is suggested to be a key mediator of pain. The IL-1B-Mediated Inflammation Model (IMPI) characterized in this study, is based on the Tet-On technology, and therefore, is doxycycline inducible. Here, we report the development and characterization of the IMPI model, including the inflammatory phenotype and induction kinetics. The basic approach used to establish this model can be extended to other cytokines/chemokines implicated in prostate disease. Furthermore, we established the role of IL-1B in mediating pelvic hypersensitivity that can be attenuated with IL-1B-blockade. Most importantly, we determined that the model recapitulates histopathological features of human inflammatory and pre-neoplastic lesions. This study provides evidence to support the notion that IL-1B-mediated chronic inflammation can induce pre-neoplastic lesions in the mouse prostate epithelium. Lastly, the genome-wide RNA expression changes mediated by IL-1B induced prostate inflammation were identified. Pathways involved in inflammation, apoptosis, oxidative stress and chemokine signaling were determined. The IMPI model is a novel platform to test anti-inflammatory therapies and will aid in the development of novel inflammatory biomarkers.